Form 8-K - Current report:
SEC Accession No. 0001096906-23-002456
Filing Date
2023-12-28
Accepted
2023-12-28 11:59:09
Documents
16
Period of Report
2023-12-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AXIM BIOTECHNOLOGIES, INC. - FORM 8-K SEC FILING axim-20231226.htm   iXBRL 8-K 23309
2 CONVERTIBLE NOTE PURCHASE AGREEMENT DATED DECEMBER 26, 2023 axim_ex10z1.htm EX-10.1 40968
3 CONVERTIBLE NOTE DATED DECEMBER 26, 2023 axim_ex10z2.htm EX-10.2 34971
8 IMAGE axim8k_1.jpg GRAPHIC 6852
  Complete submission text file 0001096906-23-002456.txt   269846

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT axim-20231226_def.xml EX-101.DEF 1842
5 XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT axim-20231226_lab.xml EX-101.LAB 20742
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT axim-20231226_pre.xml EX-101.PRE 13772
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT axim-20231226.xsd EX-101.SCH 2378
10 EXTRACTED XBRL INSTANCE DOCUMENT axim-20231226_htm.xml XML 2445
Mailing Address 6191 CORNERSTONE COURT, E SUITE 114 SAN DIEGO CA 92121
Business Address 6191 CORNERSTONE COURT, E SUITE 114 SAN DIEGO CA 92121 (212) 751-0001
AXIM BIOTECHNOLOGIES, INC. (Filer) CIK: 0001514946 (see all company filings)

EIN.: 274092986 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-54296 | Film No.: 231520975
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)